Gullà et al. [13] have found that the PRMT5 inhibitor EPZ015666 induces cell autophagy via the PRMT5/TRIM21/IKKB axis, which is identifying PRMT5 as a promising therapeutic target in MM. This evidence concerns the gene PRMT5 and Miyoshi myopathy.